Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Aldosterone synthase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Aldosterone synthase is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone. It is a protein which is only expressed in the zona glomerulosa of the adrenal cortex and is primarily regulated by the renin–angiotensin system. It is the sole enzyme capable of synthesizing aldosterone in humans and plays an important role in electrolyte balance and blood pressure.
Inhibitors of the Human Aldosterone Sythase CYP11B2
ActiveUS20110112067A1Promote degradationImprove survival rateBiocideOrganic chemistryDiseaseAldosterone Synthase Deficiency
The invention provides compounds of the general formula (I)which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and / or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.
Owner:ELEXOPHARM
Aryl pyridine as aldosterone synthase inhibitors
InactiveUS20100292225A1Improve adverse effectsSuppression problemBiocideSenses disorderArylAldosterone Synthase Deficiency
Owner:NOVARTIS AG
6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2
ActiveUS20110118241A1Promote degradationImprove survival rateBiocideOrganic chemistryAldosterone Synthase DeficiencyIsrapafant
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and / or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).
Owner:ELEXOPHARM
Dihydroquinoline-2-one derivatives
ActiveUS20130072679A1Good blood pressureImprove cardiac functionGroup 4/14 element organic compoundsUrinary disorderAldosterone Synthase DeficiencyPrimary aldosteronism
The invention provides novel compounds having the general formula (I)wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
Owner:F HOFFMANN LA ROCHE INC
Pyrazolopyridyl compounds as aldosterone synthase inhibitors
This invention relates to pyrazolopyridyl compounds of the structural formula:or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
Owner:MERCK SHARP & DOHME LLC
New bicyclic dihydroisoquinoline-1-one derivatives
ActiveUS20130143863A1Good blood pressureImprove cardiac functionBiocideOrganic chemistryAldosterone Synthase DeficiencyNephrosis
The invention provides novel compounds having the general formula (I)wherein R1, R2, R3, R4, R5, R6, A1, A2, A3, A4, A5 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
Owner:F HOFFMANN LA ROCHE & CO AG
5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
InactiveUS20120071512A1Improve adverse effectsSuppression problemBiocideSenses disorderAldosterone Synthase DeficiencyActive agent
Owner:NOVARTIS AG
Aldosterone synthase inhibitors
ActiveUS20140323468A1Useful in treatmentBiocideOrganic chemistryAldosterone Synthase DeficiencyDisease
Owner:BOEHRINGER INGELHEIM INT GMBH
Spirodiamine derivatives as aldosterone synthase inhibitors
ActiveUS10035804B2Organic active ingredientsOrganic chemistryAldosterone Synthase DeficiencyBiochemistry
Owner:F HOFFMANN LA ROCHE & CO AG
Imidazole derivatives as aldosterone synthase inhibitors
Owner:NOVARTIS AG
Inhibitors of the human aldosterone synthase CYP11B2
ActiveUS8541404B2Improve survival rateReduce morbidityBiocideOrganic chemistryDiseaseAldosterone Synthase Deficiency
The invention provides compounds of the general formula (I)which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and / or disorders or diseases that are mediated by 11β-hydroxylase (CYP11B1) with these compounds.
Owner:ELEXOPHARM
Aldosterone synthase inhibitors
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzoxazolone derivatives as aldosterone synthase inhibitors
InactiveUS20120071514A1Improve adverse effectsSuppression problemBiocideSenses disorderAldosterone Synthase DeficiencyBenzoxazole
Owner:NOVARTIS AG
Dihydroquinoline-2-one derivatives
ActiveUS9260408B2Group 4/14 element organic compoundsUrinary disorderAldosterone Synthase DeficiencyMedicine
The invention provides novel compounds having the general formula (I)wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
Owner:F HOFFMANN LA ROCHE & CO AG
Aldosterone synthase inhibitors
ActiveUS9334285B2Lower Level RequirementsUseful in treatmentOrganic active ingredientsOrganic chemistryDiseaseAldosterone Synthase Deficiency
Owner:BOEHRINGER INGELHEIM INT GMBH
Imidazole derivatives as aldosterone synthase inhibitors
InactiveUS20130065893A1Increased collagen formationBiocideSenses disorderAldosterone synthaseActive agent
Owner:NOVARTIS AG
6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase CYP11B2
ActiveUS8685960B2Improve survival rateReduce morbidityBiocideOrganic chemistryAldosterone Synthase DeficiencyPyridine
The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and / or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1).
Owner:ELEXOPHARM
Biomarkers of Mineralocorticoid Receptor Activation
ActiveUS20160362744A1Precision therapyMetabolism disorderMicrobiological testing/measurementGelatinasesAldosterone Synthase Deficiency
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Aldosterone synthase inhibitors
ActiveUS20130317057A1BiocideOrganic chemistryAldosterone Synthase DeficiencyElevated aldosterone levels
The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.
Owner:MERCK SHARP & DOHME LLC
Pet radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism
A functional PET imaging method is disclosed for differentiation between bilateral hyperplasia and unilateral adenoma comprising (1) introducing a radioactively labelled CYP11 B2 (aldosterone synthase) inhibitor which binds selectively to CYP11 B2 (aldosterone synthase) relative to CYP11 B1 (11β-hydroxylase) into a mammal with adrenal glands and (2) conducting positron emission tomography (PET) in the region of the adrenal glands to obtain a functional PET image of the adrenal glands. Also disclosed are radioactive tracer compounds suitable for use in this method, precursors for making the same, and a process for making the radioactive tracer compounds capable of being conducted as a rapid one-pot reaction.
Owner:UNIV DES SAARLANDES +1
New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
The invention relates to a phosphate salt or a nitrate salt of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and / or therapeutic treatment of aldosterone synthase and / or aromatase mediated diseases or disorders.
![New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor](https://images-eureka.patsnap.com/patent_img/6a235ade-92be-4fac-b1b7-e9994235cc15/US20140364470A1-20141211-D00001.png "New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor")
![New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor](https://images-eureka.patsnap.com/patent_img/6a235ade-92be-4fac-b1b7-e9994235cc15/US20140364470A1-20141211-D00002.png "New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor")
![New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor](https://images-eureka.patsnap.com/patent_img/6a235ade-92be-4fac-b1b7-e9994235cc15/US20140364470A1-20141211-D00003.png "New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor")
Owner:RECORDATI AG
Biomarkers of Mineralocorticoid Receptor Activation
InactiveUS20110257140A1Precision therapyOrganic active ingredientsMetabolism disorderGelatinasesAldosterone Synthase Deficiency
The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and / or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and / or of the SERPINA3 gene.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Aldosterone synthase inhibitor
ActiveUS10822332B2Decreased and very low aromatase activityDegreeOrganic active ingredientsMetabolism disorderAldosterone Synthase DeficiencyPediatric patient
Owner:DAMIAN PHARMA AG
Imidazole derivatives as aldosterone synthase inhibitors
InactiveCN102666535AOrganic active ingredientsSenses disorderAldosterone Synthase DeficiencyActive agent
Owner:NOVARTIS AG
Benzoxazolone derivatives as aldosterone synthase inhibitors
Owner:NOVARTIS AG
Aryl-pyridine derivatives as aldosterone synthase inhibitors
Owner:NOVARTIS AG
Aryl-pyridine derivatives as aldosterone synthase inhibitors
InactiveUS20120316195A1Increased collagen formationEffective treatmentBiocideNervous disorderAldosterone Synthase DeficiencyAryl
Owner:NOVARTIS AG
New bicyclic dihydroquinoline-2-one derivatives
ActiveUS20130079365A1Good blood pressureImprove cardiac functionBiocideOrganic chemistryAldosterone Synthase DeficiencyPrimary aldosteronism
The invention provides novel compounds having the general formula (I)wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 A3 and n are as described herein, compositions including the compounds and methods of using the compounds.The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
Owner:F HOFFMANN LA ROCHE INC
Aryl pyridine as aldosterone synthase inhibitors
InactiveUS20130035354A1Increased collagen formationBiocideSenses disorderAldosterone Synthase DeficiencyAryl
Owner:NOVARTIS AG
Non-invasive diagnostic imaging agent for heart disease
InactiveUS20190255199A1Pharmaceutical delivery mechanismRadioactive preparation carriersAldosterone Synthase DeficiencyImaging agent
The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient.
Owner:NIHON MEDI PHYSICS CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com